openPR Logo
Press release

Computed Tomography to Drive The Orally Disintegrating Tablet Market

02-22-2022 10:39 AM CET | Health & Medicine

Press release from: Persistence Market Research

Computed Tomography to Drive The Orally Disintegrating Tablet

The Orally Disintegrating Tablet Market is expected to climb up the ladder of persistence in the next decade. With various healthcare apps on the anvil, there are also mindfulness apps being tabled. They fall in the category of "Wellness apps". With the world wishing for the post-Covid era to function smoothly, these wellness apps are expected to take the healthcare vertical by storm further.

Improvements in drug delivery mechanism offering quicker onset of action with superior bioavailability per dose have transformed characteristics of orally administered drugs with the development of orally disintegrating tablets (ODTs). The global orally disintegrating tablets market was valued at nearly US$ 12 Bn in 2018 and will exhibit a solid CAGR during the forecast period (2019 - 2029).

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/14572

There has been growing preference among consumers and patients for orally disintegrating tablets attributed to increasing applications in treatment of diseases related to central nervous system (CNS), gastrointestinal (GI), cardiovascular disorders, and allergy. Bayer's acquisition of Merck's consumer care unit was aimed at gaining shares in ODTs. Claritin, an ODT received through this acquisition, was the largest revenue generating drug for allergy in the U.S. that year.

Company Profiles:

Teva Pharmaceutical Industries Ltd.
Novartis AG
AstraZeneca
Mylan N.V.
Pfizer Inc.
Johnson & Johnson Services, Inc.
F. Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Bausch Health
GlaxoSmithKline plc.
Sun Pharmaceutical Industries Ltd.
Bayer AG
Eli Lily and Company
Dr. Reddy's Laboratories Ltd.
Takeda Pharmaceutical Company Limited

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/14572

Key Takeaways - Orally Disintegrating Tablets Market Study

CNS diseases remain the primary area of application for orally disintegrating tablets. Researchers and healthcare providers are increasingly focusing on medical conditions such as encephalitis, autism, Alzheimer's disease, schizophrenia, depressive disorders and others to increase the application of orally disintegrating tablets.
Formulation process of orally disintegrating tablets is usually patented by manufacturers depending on the technology employed during the production such as lyophilization, freeze drying, and floss formation. Many technologies such as ZYDIS®, LYOC® and QUICKSOLV® are dependent on freeze drying method.
Easy disintegration of orally disintegrating tablets in saliva within a few seconds and accuracy of dose as compared to liquid forms and chewable tablet are expected to increase the adoption of ODTs in diseases such as ulcers of throat.

Attributed to consumers facing swallowing problems, bitter taste of drugs, and patient incompliance, manufacturers are focusing to improve drug formulations. This would help them gain an edge in terms of innovation, further favoring the growth of orally disintegrating tablets market.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/14572

Key Manufacturers Exploring New Business Models

The global orally disintegrating tablets market is fragmented with low entry barriers inspiring generic manufacturers to tap market opportunities in the form of ANDA, arising from the expiry of patent regime of approved drugs. For instance, Mylan N.V. launched Lansoprazole DR ODT, a generic version of Takeda's Prevacid® SoluTab DR ODT. The entry of The Himalaya Drug Company LTD. and Banyan Botanicals with new herbal ODT product offerings in next few years is expected to increase product lines and extension in ODTs market.

Complete Report Details@ https://www.persistencemarketresearch.com/market-research/orally-disintegrating-tablet-market.asp

Report Inclusions

Persistence Market Research offers a unique perspective and actionable insights on the Orally Disintegrating Tablets landscape in its new study, presenting historical demand assessment from 2014 - 2018 and projections from 2019 - 2029 on the basis of drug class (anti-psychotics, anti-epileptics, CNS stimulants, anxiolytics, anti-Parkinsonian drugs, anti-hypertensives, NSAIDS, anti-allergy drugs, proton pump inhibitors), disease indication (CNS diseases, GI diseases, allergy, CVS disorders), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online pharmacies), and five key regions.

Related Reports:

Allergy Shots Market - https://www.persistencemarketresearch.com/market-research/allergy-shots-market.asp

Uveitis Treatment Market - https://www.persistencemarketresearch.com/market-research/uveitis-treatment-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Computed Tomography to Drive The Orally Disintegrating Tablet Market here

News-ID: 2559735 • Views:

More Releases from Persistence Market Research

Non-GMO Food Market Value to Hit $120.1 Bn by 2032 Driven by Health & Clean Label Demand
Non-GMO Food Market Value to Hit $120.1 Bn by 2032 Driven by Health & Clean Labe …
Overview of the Market The global non-GMO food market is experiencing robust momentum as consumers increasingly demand transparency, sustainability, and natural food options. According to market projections, the industry is set to grow from US$ 70.7 billion in 2025 to US$ 120.1 billion by 2032, reflecting an impressive CAGR of 7.9% during the forecast period. This growth is propelled by heightened awareness of food safety, rising health consciousness, and consumer concerns
U.S. Nuts Market to Reach $16,026.1 Mn by 2032 Driven by Healthy Snacking Trends
U.S. Nuts Market to Reach $16,026.1 Mn by 2032 Driven by Healthy Snacking Trends
Overview of the U.S. Nuts Market The U.S. nuts market is projected to rise from US$ 10,976.6 Mn in 2025 to US$ 16,026.1 Mn by 2032, registering a steady CAGR of 5.6% during the forecast period. Nuts are increasingly being recognized as a staple in the American diet due to their nutritional profile, health benefits, and versatility across food and beverage applications. The market is being shaped by rising consumer awareness
Champagne Market to reach US$11,189.6 Mn by 2032, driven by luxury demand & trends
Champagne Market to reach US$11,189.6 Mn by 2032, driven by luxury demand & tren …
Overview of the Market The global champagne market has remained a symbol of celebration, luxury, and fine living for centuries, and its demand continues to evolve alongside changing consumer lifestyles and preferences. According to market estimates, the champagne market size is projected to increase from US$ 7,923.0 million in 2025 to US$ 11,189.6 million by 2032, reflecting a compound annual growth rate (CAGR) of 5.1%. This growth trajectory highlights the premiumization
Europe Olive Oil Market Growth Driven by Health Trends, to Reach $15.7 Bn by 2032
Europe Olive Oil Market Growth Driven by Health Trends, to Reach $15.7 Bn by 203 …
Market Overview The Europe olive oil market is poised for steady expansion, estimated to grow from US$12.6 billion in 2025 to US$15.7 billion by 2032, recording a compound annual growth rate (CAGR) of 3.6% during the forecast period. Olive oil holds a central place in European diets, both as a traditional culinary staple and as a modern health-conscious choice. The growth trajectory is strongly supported by rising consumer awareness regarding the

All 5 Releases


More Releases for ODT

Phase 3 Clinical Trial for Major Depressive Disorder Treatment Market Begins 202 …
The Global Major Depressive Disorder Market size reached US$ 6.84 billion in 2024 and is expected to reach US$ 14.57 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033. The Major Depressive Disorder Market report, released by DataM Intelligence, offers comprehensive insights and thorough analysis of major market trends, growth prospects, and emerging challenges. With a strong focus on actionable intelligence, DataM Intelligence equips businesses with
Orally Disintegrating Tablet (ODT) Market Analysis, Size, Current Scenario and F …
Orally disintegrating tablet (ODT) market is anticipated to grow at a significant CAGR during the forecast period. According to the US Food and Drug Administration (FDA), ODT's are a solid dosage form that contains a medicinal substance or active ingredient which rapidly disintegrates when placed upon the tongue within a second. The major factor for the growth of the global orally disintegrating tablet (ODT) market during the forecast period is
Orally Disintegrating Tablet (ODT) Market Share 2021 Growth Challenges, Opportun …
The global orally disintegrating tablet (ODT) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). According to the US Food and Drug Administration (FDA), ODT’s are a solid dosage form that contains a medicinal substance or active ingredient which rapidly disintegrates when placed upon the tongue within a second. The major factor for the growth of the global orally disintegrating tablet (ODT) market during the
Orally Dissolving Tablets (ODT) Excipient Market global outlook and forecast 202 …
The Global Orally Dissolving Tablets (ODT) Excipient Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Orally Dissolving Tablets (ODT) Excipient makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and
Investigation announced for Long-Term Investors in shares of Odonate Therapeutic …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Odonate Therapeutics, Inc.. Investors who are current long term investors in Odonate Therapeutics, Inc. (NASDAQ: ODT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: ODT stocks follows a lawsuit filed against Odonate
Deadline on Nov. 16th coming up in Lawsuit for Investors in Odonate Therapeutics …
The Shareholders Foundation announced that a deadline is coming up on November 16, 2020 in the lawsuit filed for certain investors of Odonate Therapeutics, Inc. (NASDAQ: ODT) over alleged securities laws violations by Odonate Therapeutics, Inc. Investors who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and there are strict and short deadlines running. Deadline: November 16, 2020. NASDAQ: ODT stockholders should contact the Shareholders Foundation at